Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Microscope in a BioEscalator Lab


Nucleome Therapeutics raises oversubscribed £37.5 million Series A financing

Nucleome Therapeutics Limited, a recently graduated BioEscalator tenant decoding the dark matter of the human genome to discover first-in-class precision medicines, today announces it has closed an oversubscribed £37.5 million Series A financing round. The funds will be used to advance the biotech company's autoimmune disease programmes, fuel the expansion of its dark genome atlas and further develop its pioneering platform.

Ochre Bio raises $30M (£27M) Series A financing for the development of RNA therapies for chronic liver diseases

Proceeds to support the development of first candidates for IND-enabling studies, as well as expand discovery and RNA chemistry capabilities to address a wider set of serious liver-related diseases. Additional capabilities create one the world’s fastest liver R&D pipelines. In a matter of days, Ochre can identify a novel target, synthesize an RNA therapy, and test it in a human liver.

Mental health in the SME community

Starting up your own business is challenging at the best of times; business plans, funding, licensing and IP are just a few of the hurdles founders face. In addition to the global pandemic and the current financial crisis in the UK, SMEs are under more pressure than ever.

BioEscalator Team
Photograph of the BioEscalator building and adjoining carpark, taken from the top of the Kennedy building © BioEscalator Oxford